|
|
|
|
New Research Report: Malaysia Pharmaceuticals & Healthcare Report Q1 2010
In BMI's Business Environment Rating (BER) matrix for Q409, Malaysia considerably improved its position in the Asia Pacific matrix, and is now ranked fifth out of the 15 key regional markets.Key attractions of the Malaysian pharmaceutical market are the...
|
|
|
Bayer Schering Pharma commences ADVISE in Asia Pacific
Bayer Schering commences ADVISE in Asia Pacific BIO BIO BIO BIO BIO BIO BIO BIO BIO BIO BIO BIO Story Bayer Schering commences ADVISE in Asia Pacific Singapore, January 26, 2010: Bayer Schering AG announced that it has started ADVISE, the Asia Pacific trial...
|
|
|
Some Blood Pressure Drugs May Stave Off Dementia
TUESDAY, Jan.12 (HealthDay News) -- Blood pressure drugs that block the protein angiotensin appear to reduce the risk of developing Alzheimer's disease and other forms of dementia, a new study finds. 'We think it [angiotensin] is one of the most important...
|
|
|
Three new Novartis medicines approved in Japan for patients with type 2 diabetes, high blood pressure and adva
nd Afinitor provide new treatment options for unmet medical needs22 Jan 2010 - Patients in Japan will benefit from the approval of three new Novartis medicines - Equa (vildagliptin), marketed as Galvus in the European Union, for the treatment of type 2 diabetes...
|
|
|
Left ventricular diastolic function improved by lowering BP
Hypertension 2010; 55: 224-225 MedWire News: Patients with hypertension who achieve greater reductions in systolic blood pressure (SBP) show improved left ventricular (LV) diastolic function relative to their peers who achieve more modest SBP reductions, study...
|
|
|
Novartis Receives Approval For Three New Medicines In Japan
Novartis has received approval for three new medicines- Equa, Exforge and Afinitor in Japan for patients with type 2 diabetes, high blood pressure and advanced kidney cancer.According to the company, Equa (vildagliptin), marketed as Galvus in the European...
|
|
|
Japan Sanctions Three Novartis Drugs for Hypertension, Advanced Renal Cancer, and Type 2 Diabetes
Japanese regulatory authorities sanctioned three Novartis drugs: Exforge for high blood pressure, Afinitor (everolimus) for advanced kidney cancer, and Equa (vildagliptin) as an oral therapy for type 2 diabetes.Exforge is a single-pill combination of Diovan ...
|
|
|
Triple approval for Novartis in Japan
Japanese regulators have approved three new Novartis medicines for use patients with type II diabetes, high blood pressure and advanced kidney cancer.Passing Equa (vildagliptin), Exforge (amlodipine) and Afinitor (everolimus) will provide new treatment...
|
|
|
Novartis receives approval for three medicines in Japan
- Switzerland-based healthcare products company Novartis AG (VTX: NOVN) announced today that three medicines were approved in Japan for patients with type 2 diabetes, high blood pressure and advanced kidney cancer.Equa has been approved in Japan for the...
|
|
|
Swiss Novartis gets Japanese approval for three medicines
- Swiss drug maker Novartis (VTX:NOVN) announced today it received marketing approval for the Equa (vildagliptin), Exforge (valsatran/amlodipine) and Afinitor (everolimus) drugs in Japan.Equa was approved for the treatment of type 2 diabetes as monotherapy...
|
|
|
Health Canada approves Novartis' Afinitor to treat patients with mRCC
Novartis Pharmaceuticals Canada Inc.(Novartis) announced today that Afinitor(R) (everolimus), a onc...Omni Hotels & Resorts partners with GHA to host "Lasso for Life" eventTop marketing representatives of Omni Hotels & Resorts and the other Global...
|
|
|
Novartis Reveals Approval Of Three Medicines In Japan - Update
1/20/2010 6:37 AM ET RELATED NEWS TOP MARKET NEWS (RTTNews) - Pharmaceutical firm Novartis (NOV) Wednesday revealed the approval of three medicines in Japan - Equa or vildagliptin for the treatment of type 2 diabetes, Exforge or valsartan/amlodipine for high...
|
|
|
Enzyme Research: Data on enzyme research reported by researchers at Duke University, Division of Endocrinology
Today's Medical & Research News Enzyme Research Data on enzyme research reported by researchers at Duke University, Division of Endocrinology January 16th, 2010 Printer-Friendly Version City:Durham State:NC Country:United States Enzyme Research Addiction...
|
|
|
Hypertension Drugs May Cut Alzheimer's Risk
Study Shows Blood Pressure Drugs Linked to Lower Risk of Dementia, Alzheimer's Disease Jan.12, 2010 -- Drugs commonly used to treat and heart disease may reduce the risk of dementia and Alzheimer's disease, a new study suggests. Boston University...
|
|
|
Report: Combo hypertension drugs could provide lower doses, be safer
FURTHER READING Company Decision Resources Novartis Person Nikhil Mehta Product amlodipine Diovan Micardis Norvasc Tareg telmisartan Topic angiotensin II receptor antagonist calcium channel blocker hypertension Pharmaceutical telmisartan Portals Pharmaceuticals...
|
|
|
Hypertension Medications Use To Prevent Dementia & Alzheimer's
"This study suggests that angiotensin receptor blockers are associated with reduced incidence and progression of Alzheimer's disease and dementia compared with other drugs for cardiovascular disease or hypertension.....As angiotensin receptor blockers and...
|
|
|
Study: Certain hypertension drugs may reduce Alzheimer's risk
by Matthew Dennis, Firstword According to a study published in the BMJ, hypertension drugs known as angiotensin receptor blockers (ARBs) may reduce the risk of developing Alzheimer's disease and dementia.Lead researcher Benjamin Wolozin of the Boston...
|
|
|
High Blood Pressure Medicines May Help Fight Dementia
A recent study by the Boson University School of Medicine shows a decrease risk of Alzheimers Disease and dementia in those taking certain medicines.There was more of a decrease for those taking Angiotensin Receptor Blockers (ABR) drugs, but the study also...
|
|
|
Some blood pressure drugs may stave off dementia
TUESDAY, Jan.12 (HealthDay News) -- Blood pressure drugs that block the protein angiotensin appear to reduce the risk of developing Alzheimer's disease and other forms of dementia, a new study finds. 'We think it [angiotensin] is one of the most important...
|
|
|
Blood pressure drugs could lower risk of Alzheimer's
Kate Kelland Medicines commonly used to treat high blood pressure and heart disease may cut the risk of developing Alzheimer's disease and dementia, US scientists said yesterday.Boston researchers found that older people taking blood pressure medications...
|
|
|
Hypertension Drugs May Cut Alzheimer's Risk
Study Shows Blood Pressure Drugs Linked to Lower Risk of Dementia, Alzheimer's Disease By Bill Hendrick WebMD Health News Reviewed By Jan.12, 2010 -- Drugs commonly used to treat and heart disease may reduce the risk of dementia and Alzheimer's disease, a...
|
|
|
Blood pressure drugs may reduce dementia risk
By Kate Kelland London - Medicines commonly used to treat high blood pressure and heart disease may cut the risk of developing Alzheimer's disease and dementia, United States scientists said on Wednesday.Researchers from Boston found that older people taking...
|
|
|
Study: Certain hypertension drugs may reduce Alzheimer's risk
Certain hypertension drugs may reduce Alzheimers risk - FirstWord Industry News January 13, 2010 Study: Certain hypertension drugs may reduce Alzheimers risk by Matthew Dennis According to a study published in the BMJ, hypertension drugs known as angiotensin...
|
|
|
Some blood pressure drugs may stave off dementia
coreAdsCreate('wnsz_20', 'loc', '100', 'wnsz_20', By Ed EdelsonDay Reporter TUESDAY, Jan.12 (Day News) -- Blood pressure drugs that block the protein angiotensin appear to reduce the risk of developing Alzheimer's disease and other forms of dementia, a new...
|
|
|
Some blood pressure drugs may stave off dementia
TUESDAY, Jan.12 (HealthDay News) -- Blood pressure drugs that block the protein angiotensin appear to reduce the risk of developing Alzheimer's disease and other forms of dementia, a new study finds. 'We think it [angiotensin] is one of the most important...
|
